TAHO obtained U.S. patent approval for TAH9901 methylphenidate transdermal patch, a transdermal ADHD treatment for pediatric ADHD.

TAHO received patent allowance from the United States Patent and Trademark Office, for the TAH9901 pediatric ADHD patch (Methylphenidate Transdermal Patch).

About TAH9901
TAH9901 is a methylphenidate transdermal patch for children with ADHD. Designed to avoid the difficulty of swallowing oral medication. The product was developed as a transdermal patch to facilitate children's use and increase the compliance for pediatric patients. According to IMS Data in 2015, the total market size of pediatric ADHD drugs in the United States is approximately NT$56 billion. The revenue generated by the methylphenidate pediatric ADHD patch will vary by the actual licensing or sales in the future.


Click the numbers in sequence.